Boltz Raises $110M Series A Led by Bessemer for Molecular-Design AI, Says Token Use Up 50x Since June
Summary
London-based Boltz, spun out of MIT in 2025, has raised a $110M Series A led by Bessemer Venture Partners with Andreessen Horowitz participating. The company says molecular-token usage among paying customers has grown 50x since its June launch of BoltzMol-1 and BoltzProt-1, and that six of the world's 20 largest pharma firms — including Pfizer, GSK, Takeda and BMS — are on contract.
Originally reported by tech.eu
Read the original article →Original headline: Boltz Raises $110M Series A Led by Bessemer for Molecular-Design AI, Says Token Use Up 50x Since June